Klama-Baryła A, Kitala D, Łabuś W, Kraut M, Glik J, Nowak M, Kawecki M
Dr Stanisław Sakiel Center for Burns Treatment, Siemianowice Śląskie, Poland; Silesian Higher Medical School in Katowice, Katowice, Poland.
Dr Stanisław Sakiel Center for Burns Treatment, Siemianowice Śląskie, Poland.
Transplant Proc. 2018 Sep;50(7):2179-2187. doi: 10.1016/j.transproceed.2017.11.079. Epub 2018 Mar 13.
Transplantation of skin cells (keratinocytes and fibroblasts) cultured in vitro is a method of choice for the treatment of severe and extensive burns in patients with a deficit of donor sites for free split-thickness skin grafts, and when the grave medical condition of the patient excludes the possibility of an operation under general anesthetic. Appropriate amounts of keratinocytes and/or fibroblasts cultured in vitro are grafted as a suspension in platelet-leukocyte-rich gel directly on the prepared acceptor site. Approximately 3 weeks are needed for autologous cell culture to grow. Allogeneic cells are obtained from patients who died before their own autologous cell transplantation. Therefore allogeneic cells are considered as ready to use product. The aim of the study was to evaluate the efficiency of in vitro cultured autologous/allogeneic skin cell grafts in the treatment of burns.
In this study a group of 68 patients hospitalized in the Dr Stanisław Sakiel Centre for Burn Treatment in Siemianowice Śląskie and treated with in vitro cultured skin cells suspended in platelet-leukocyte-rich gel were analyzed.
Autologous/allogeneic keratinocytes and fibroblasts transplantation hastens wound closure.
A major factor in burn treatment is early application of skin cells, so allogeneic cells are more appropriate, because these cells are an on-shelf product. It is especially important in groups of patients with third-degree burn greater than 40%. Allogeneic cells application does not increase hospitalization length in comparison to autologous cells, meaning usage of allogeneic cells in burns treatment is as efficient as autologous cells.
体外培养的皮肤细胞（角质形成细胞和成纤维细胞）移植是治疗严重大面积烧伤患者的一种首选方法，这些患者缺乏供体部位进行游离中厚皮片移植，且患者严重的病情排除了全身麻醉下手术的可能性。将适量体外培养的角质形成细胞和/或成纤维细胞作为悬浮液接种在富含血小板 - 白细胞的凝胶中，直接移植到准备好的受区。自体细胞培养生长大约需要3周时间。同种异体细胞来自在自体细胞移植前死亡的患者。因此，同种异体细胞被视为即用型产品。本研究的目的是评估体外培养的自体/同种异体皮肤细胞移植治疗烧伤的效果。
本研究分析了一组68例在西里西亚省谢米亚诺维采的斯坦尼斯瓦夫·萨基尔烧伤治疗中心住院的患者，他们接受了悬浮在富含血小板 - 白细胞凝胶中的体外培养皮肤细胞治疗。
自体/同种异体角质形成细胞和成纤维细胞移植可加速伤口愈合。
烧伤治疗的一个主要因素是早期应用皮肤细胞，因此同种异体细胞更合适，因为这些细胞是现成的产品。这在三度烧伤面积大于40%的患者群体中尤为重要。与自体细胞相比，应用同种异体细胞不会增加住院时间，这意味着在烧伤治疗中使用同种异体细胞与自体细胞一样有效。
